Results 51 to 60 of about 72,295 (296)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease

World Journal of Gastroenterology, 2022
BACKGROUND Tumor necrosis factor-alpha inhibitors, including infliximab and adalimumab, are effective medical treatments for perianal fistulising Crohn’s disease (CD), but not all patients achieve fistula healing. AIM To determine the correlation between
B. Gu, K. Venkatesh, A. Williams, W. Ng, C. Corte, A. Gholamrezaei, S. Ghaly, W. Xuan, S. Paramsothy, S. Connor   +9 more
semanticscholar   +1 more source

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study

Arthritis & Rheumatology
Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with ...
X. Baraliakos, M. Østergaard, D. Poddubnyy, D. M. van der Heijde, A. Deodhar, P. M. Machado, V. Navarro-Compán, Kay-Geert A. Hermann, M. Kishimoto, Eun Young Lee, L. Gensler, U. Kiltz, M. Eigenmann, P. Pertel, A. Readie, H. Richards, B. Porter, J. Braun   +17 more
semanticscholar   +1 more source

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Pharmacology Research & Perspectives, 2021
The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to ...
Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li   +8 more
doaj   +1 more source

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years. Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily ...
R. Fleischmann, Jerzy Świerkot, Sara K. Penn, P. Durez, L. Bessette, X. Bu, N. Khan, Yihan Li, C. Peterfy, Yoshiya Tanaka, E. Mysler   +10 more
semanticscholar   +1 more source

Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy.

American journal of ophthalmology-glaucoma, 2022
PURPOSE To evaluate the effectiveness and reasons for discontinuation including the side effect profiles of adalimumab in a real-world setting. DESIGN A retrospective clinical cohort study was performed.
L. Eurelings, T. Missotten, M. V. van Velthoven, P. V. van Daele, J. V. van Laar, P. V. van Hagen, A. Thiadens, S. Rombach   +7 more
semanticscholar   +1 more source

A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab

Case Reports in Rheumatology, 2013
Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents.
Hakan Ozkan, Ahmet Seckin Cetinkaya, Tekin Yildiz, Tahsin Bozat   +3 more
doaj   +1 more source

Can adalimumab prevent from acute effects of lipopolysaccharide induced renal injury in rats? [PDF]

Acta Cirúrgica Brasileira
Purpose: Lipopolysaccharides is well-known in the acute renal injury process. It causes widespread activation of inflammatory cascades. Tumor necrosis factor (TNF)-α and interleukin (Il)-6 are essential proinflammatory cytokines that can induce the ...
Nuket Özkavruk Eliyatkın, Akif İşlek, Selim Durmaz, Fevzi Ayyıldız, Ömer Rahman   +4 more
doaj   +1 more source

Adalimumab Monotherapy in the Treatment of Idiopathic Multifocal Choroiditis: A Case Report

Case Reports in Ophthalmology, 2022
In this study, we report a case of multifocal choroiditis that was successfully treated with adalimumab monotherapy. A 25-year-old male presented with a history of bilateral multifocal choroiditis which was resistant to a combination of azathioprine ...
Arash Maleki, Andrew Philip, C. Stephen Foster   +2 more
doaj   +1 more source

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

American Journal of Clinical Dermatology, 2022
BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the FDA requirements for designation as an ‘interchangeable ...
A. Menter, Stanley Cohen, J. Kay, V. Strand, A. Gottlieb, S. Hanauer, Sravan Kumar Eduru, Susanne Buschke, B. Lang, Karl-Heinz Liesenfeld, J. Schaible, Dorothy McCabe   +11 more
semanticscholar   +1 more source

Marked improvement in nail psoriasis during treatment with adalimumab [PDF]

, 2009
BACKGROUND: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients' quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options ...
Irla, N, Yawalkar, N
core   +2 more sources